Navi Mumbai, India (PressExposure) April 06, 2012 -- The report titled "The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment" provides a comprehensive analysis on the Pharmaceutical market in the US covering various aspects such as market size of the pharmaceutical industry, market segmentation by Branded and Generic drugs, and Prescribed and OTC drugs and Biologics and specialty drugs segments. The report also provides information on the government regulations, export and imports of pharmaceuticals and medicines. The report also entails competitive landscape and profiles of the major players operating in the industry. The future projections are included to provide an insight on the prospects in the US pharmaceutical industry. http://bharatbook.com/market-research-reports/healthcare-market-research-report/the-us-pharmaceutical-market-outlook-to-2016-evolving-opportunities-in-the-biologics-segment.html
The US Pharmaceutical market is the largest pharmaceutical market in the world which has registered a marginal slowdown in the growth rate over the period. The slowing growth rate can be attributed to an increasing number of drugs losing its patent security and surrogated by generic equivalents. In terms of sales value, the US pharmaceutical industry has recorded consistent growth at a 5 year CAGR of 3.2% over the period. The sales of Pharmaceuticals in the US grew from USD ~ billion in 2005 to USD ~ billion in 2010. Industry Analysis
Branded drugs hold the major market share in the total pharmaceutical drugs sales in the US. In 2010, branded drugs accounted for ~ of the total drugs sold, but this market share decreased over the period from ~ in 2005. The sales of branded drugs grew from USD ~billion in 2005 to USD ~ billion in 2010 at a CAGR of ~. Generic drugs, which showcased a growth in the market share over the period from ~ share in 2005 to ~ in 2010 and posted sales of USD ~ billion, which has grown at a 5 year CAGR of 9.4% from sales worth of USD ~ billion in 2005.
The biopharmaceutical industry is one of the most research concentrated industries in the US. The expenditure on biopharmaceutical research and development has showcased a dependable growth over the period. The expenditure has grown from USD ~ billion in 2005 to USD ~ billion in 2010 at a CAGR of 5.4%. Avastin, Rituxan, Enbrel and Remicade among the world's top selling biologics and each recorded sales above USD ~ billion in the US in 2010. Bristol-Myers Squibb is the largest company in the US in terms of biopharmaceutical drugs sales. The company held a market share of ~% and recorded sales of USD ~ billion. The US biologic drugs market is estimated to grow at a 5 year CAGR of 8.1% from 2011 to reach USD ~ billion by 2016.
The US pharmaceutical industry is expected to grow over the period at a CAGR of 4.8% with projected sales of USD ~ billion in 2015. It is estimated that the research and development productivity will increase and will trigger the growth in the market. Additionally the companies will focus on developing pharmaceutical drugs for personalized healthcare.
The US pharmaceutical industry witnessed revenues worth of USD ~ billion in 2011. Pfizer is the largest company with a market share of ~ and sales of USD ~ billion in 2011. Pfizer's blockbuster drug, Lipitor played a major role in helping the company secure its number one position.
For more information kindly visit :
The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter: http://twitter.com/#!/Sandhya3B